Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts March 4-7, 2018     Cardiovascular Update CROI 2018 - by Priscilla Hsue MD Professor of Medicine, UCSF - (05/11/18)   HIV Prevention at CROI 2018 and PrEP Updates on PrEP - Disparities; Current & Future; Delivery/Use/Barriers; Women. Transmission Clusters - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (04/9/18)   Clinical Pharmacology at CROI 2018 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/9/18)   CROI 2018 Summary Report, Eric Daar M.D. - Boston, MA Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (04/4/18)   Summary from CROI 2018 for viral Hepatitis HCV micro-elimination in HIV/HCV coinfection: successes and challenges - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/29/18)   The Kidney at CROI 2018 -Christina Wyatt MD - Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (03/16/18)   Antiretroviral Therapy CROI 2018 New Agents/Combinations - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill (03/13/18)   CROI 2018: Comorbidities and Inflammation - David H Shepp, MD Associate Professor of Medicine Zucker School of Medicine at Hofstra-Northwell Manhasset, NY(03/13/18)   New Positive Data on Trogarzo™ (ibalizumab-uiyk) Injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections (03/09/18)   Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys - (03/05/18)   Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - (03/07/18)   ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis - (03/07/18)   ---------------------------------------------------------------   Trends in Unsuppressed HIV RNA After Linkage to Care Among Key Populations - (07/24/18)   HIV Viral Suppression Assessed by Two Metrics in North Carolina during 2016 - (07/24/18)   Depression (24%) is Associated with Missed Visits, Emergency Room Utilization, and Drug Use - (07/24/18)   CLINIC-LEVEL FACTORS ASSOCIATED WITH TIME TO VIRAL SUPPRESSION IN WASHINGTON DC - (07/24/18)   Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity - (07/05/18)   FAT QUALITY IS INDEPENDENTLY ASSOCIATED WITH CARDIOMETABOLIC RISK IN HIV INFECTION - (07/05/18)   HIV Immune Dysregulation Predicts Lean Tissue & Fat Changes During Chronic Disease - (07/05/18)   Lower Pretreatment Gut Integrity Associated With Fat Gains on Antiretrovirals - (07/05/18)   SWITCHING TO TAF IN EVG-BASED REGIMENS: CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY - (05/30/18)   Seminal Tenofovir concentrations, viral suppression and semen quality with TAF vs TDF - (05/30/18)   Pharm: Comparison of Relative Bioavailability of TIVICAY Immediate Release and Dispersible Pediatric Tablets to Immediate Release TIVICAY Adult Tablets - (05/28/18)   Carotid IMT Progression is Most Striking in First 48 Weeks of Antiretroviral Therapy - (05/23/18)   Effects of Antiretroviral Therapy on Allele-Associated Lipoprotein(a) Levels in HIV - (05/23/18)   HIV+ Men Matched By Age And FRS With Controls Have More Cardiovascular Events - (05/22/18)   CARDIAC VENTRICULAR DISFUNCTION IN YOUNG VERTICALLY INFECTED HIV PATIENTS - (05/22/18)   Myocardial Steatosis in Relation to Cardiac Dysfunction Among Women Living with HIV - (05/22/18)   Coronary Arterial Wall Thickening and Association with Myocardial Diastolic Function in HIV - (05/22/18)   Mental Disability in HIV- Misunderstood & Unmet Need - (05/15/18)   The Mediterranean Portfolio diet in HIV dyslipidaemia: a pilot randomised controlled trial - (05/14/18)   Insurer Denial of DAA Prescription Requests Rising Across United States - Mark Mascolini (05/14/18)   Longitudinal trajectory of brain volume and cortical thickness in primary infection - (05/04/18)   IMPACT OF PREVIOUS M184V ON VIROLOGICAL OUTCOME OF SWITCH TO 3TC-BASED DUAL THERAPIES - (05/01/18)   Rapid reduction in HIV diagnoses after targeted PrEP implementation in New South Wales, Australia - (04/13/18)   PrEP at CROI 2018 Report 2: uptake, HIV incidence; barriers/challenges - (04/10/18)   Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts - (04/10/18)   "RAPID REDUCTION IN HIV DIAGNOSES AFTER TARGETED PrEP IMPLEMENTATION IN NSW, AUSTRALIA" - PrEP NATAP Report 3 - (04/10/18)   Female HIV acquisition per sex act is elevated in late pregnancy and postpartum - (04/10/18)   Vaginal Contraceptive Hormone Exposure Profoundly Altered by EFV- And ATV/r-based ART AIDS Clinical Trials Group A5316 - (04/10/18)   RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE ONCE DAILY PLASMA AND INTRACELLULAR PHARMACOKINETICS - (04/10/18)   PrEP at CROI 2018 - (04/10/18)   Factors Impacting Appropriate HIV/STI Screening and PrEP Persistence in Primary Care - (04/10/18)   STIMULANT USE AND CONDOMLESS SEX WITH MULTIPLE PARTNERS: EFFECT ON PREP ADHERENCE - (04/9/18)   High Discontinuation of Pre-Exposure Prophylaxis Within Six Months of Initiation - (04/9/18)   Predictors of Willingness to Take PrEP Among Black and Latina Transgender Women - (04/9/18)   Reported PrEP use among HIV-negative partners of US MSM receiving HIV medical care - (04/6/18)   HIV Risk Perception Among Men who have Sex with Men (MSM): A Randomized Controlled Trial - (04/6/18)   NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006-2016 - (04/6/18)   DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007-2015 - (04/6/18)   Durability of Financial Incentives Effect on Viral Suppression and Continuity in Care - (04/6/18)   ART Reduces T Cell Activation and Immune Exhaustion Markers in HIV Controllers - (04/6/18)   In Silico Drug Interaction of Long-acting Rilpivirine and Cabotegravir With Rifampin - (04/6/18)   Female HIV acquisition per sex act is elevated in late pregnancy and postpartum - (04/6/18)   Reported PrEP use among HIV-negative partners of US MSM receiving HIV medical care - (04/5/18)   Assessing PrEP Needs Among Heterosexuals and People Who Inject Drugs, Washington, DC - (04/5/18)   Monitoring PrEP Use Among Washington State MSM: Results of an Internet Survey - (04/5/18)   HIGH SEROCONVERSION RATES FOLLOWING PrEP DISCONTINUANCE IN A MONTREAL CLINIC - (04/5/18)   DECREASES IN HIV INCIDENCE IN A MONTREAL CLINIC COINCIDE WITH EXPANDING PREP USE - (04/5/18)   PrEP USE HISTORY OF PERSONS NEWLY DIAGNOSED WITH HIV: NEW YORK CITY, 2015-2017 - (04/5/18)   Trends in PrEP Uptake, Adherence, and Discontinuation Among YMSM in Chicago - (04/5/18)   Patterns and Correlates of Participant Retention in the U.S. PrEP Demonstration Project - (04/5/18)   High Discontinuation of Pre-Exposure Prophylaxis Within Six Months of Initiation- Los Amgeles - (04/5/18)   INCREASING PREP UPTAKE, PERSISTENT DISPARITIES, IN AT-RISK PATIENTS IN A BOSTON COMMUNITY HEALTH CENTER - (04/5/18)   Seroconversion on PrEP [4th case]: A Protocol for Untangling Adherence vs. Resistance Failure - (04/4/18)   A Public Health Approach to Viremic Individuals With PrEP-resistant Virus - (04/4/18)   HIV Diagnoses Among People Who Inject Drugs -United States, 2010-2016 - (04/4/18)   Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts - (04/4/18)   PREDICTORS OF PrEP ELIGIBILITY AMONG AT-RISK WOMEN IN THE SOUTHERN UNITED STATES - (03/29/18)   HIV BIOMEDICAL PREVENTION AMONG U.S. WOMEN: KNOWLEDGE, BELIEFS, AND PRACTICES - (03/29/18)   The PREP Cascade at NYC Sexual Health Clinics: Navigation is the Key to Uptake - (03/29/18)   PrEP Implementation and Persistence in a County Health Department in Atlanta, GA - (03/29/18)   Summary from CROI 2018 for viral Hepatitis HCV micro-elimination in HIV/HCV coinfection: successes and challenges - (03/29/18)   A Multicenter Registry in HIV/HCV Co-infected Patients Initiating Ledipasvir/Sofosbuvir - (03/29/18)   HCV RNA and Antigen Detection for Diagnosis of Acute Hepatitis C Among MSM on PreP..... In the ANRS IPERGAY PrEP trial among high risk MSM - (03/29/18)   Nine of 100 MSM in German Cohort Get HCV Reinfection Every Year in DAA Era - Mark Mascolini (03/29/18)   Disparities in PrEP Uptake Among Primary Care Patients - (03/28/18)   Getting to Zero New Diagnoses in San Francisco: The Potential Role of PrEP - (03/28/18)   The PrEP Care Continuum and HIV Racial Disparities among Men Who Have Sex with Men (03/28/18)   By Race/ethnicity, Blacks Have Highest Number Needing PrEP in the United States, 2015 (03/28/18)   CVD Factors Tied to Cognitive Impairment Differ in Women and Men With HIV - Mark Mascolini (03/28/18)   The association of pain and long-term opioid therapy with HIV treatment outcomes - Chronic Pain Tied to Virologic Failure, While Long-Term Opioids Lower Odds of Failure - Mark Mascolini (03/28/18)   HCV incidence in HIV-infected and in PrEP-using MSM - New HCV Rate Similar in HIV+ MSM and HIV- MSM on PrEP in France - Mark Mascolini (03/27/18)   Olfactory Mucosa HIV RNA Correlates With CSF RNA in People On/Off ART - Mark Mascolini (03/26/18)   QUANTIFICATION OF REPLICATION COMPETENT LATENT HIV-1 IN GALT AND SEMEN - Mark Mascolini (03/26/18)   High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation - Mark Mascolini (03/26/18)   Pharmacokinetcs of dolutegravir with and without darunavir/cobicistat in healthy volunteers (03/26/18)   Low Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations Across Botswana (03/26/18)   High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation (03/26/18)   Resistance Analyses of Bictegravir/Emtricitabine/Tenofovir Alafenamide Switch Studies (03/26/18)   [Bictegravir] Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1 (03/26/18)   PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART (03/26/18)   Combined Effects of Bisphosphonates and TDF→TAF Switch in HIV+ Adults With Low BMD - Mark Mascolini (03/26/18)   Life Extectancy, Mental Comorbidities, Inflammation, /Anti-Inflammatories Drug Research - Life Expectancy Lags in Some HIV Groups: Black MSM, Drug Injectors, HCV+ (03/26/18)   Fat and Lean Mass Changes Similar With and Without HIV in Ireland Cohort - Mark Mascolini (03/23/18)   Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women - Cervical Outcomes Similar With Immediate Cryotherapy and Standard Cytology in HIV+ Women - Mark Mascolini (03/23/18)   CDC: Clinical outcomes of US young black men with HIV receiving medical care, 2009-2014 - More ART for Young Black Men in US, But Adherence and Suppression Flat - Mark Mascolini (03/23/18)   HIV Transmission Risk Higher With HIV+ Opioid Misusers, Especially Injectors - less adherence, viral suppression/more condomless sex - Mark Mascolini (03/23/18)   Comparing Strategies for Reducing Myocardial Infarction Rates in HIV Patients - Mark Mascolini (03/23/18)   HIV Diagnosis After Age 50 Often Delayed Despite Clear Clues - Should age-associated, Non-AIDS conditions Invite HIV Testing, YES - Mark Mascolini (03/23/18)   Prognosis Prediction in START Similar with IL-6, D-dimer, CD8s, and CD4:CD8 Ratio - Mark Mascolini (03/23/18)   New HCV Infections Still Rising Among MSM With HIV in France - Mark Mascolini (03/22/18)   Ablation Outcomes for HIV Infected and Uninfected Patients with High-Grade Anal Dysplasia (03/21/18)   CHANGES IN BRAIN VOLUME AND COGNITION IN MICE EXPOSED IN UTERO TO ABC/ 3TC-ATV/ RTV (03/21/18)   Safety, Pharmacokinetics, and Efficacy of FTC/TAF in HIV-Infected Adolescents (12-18 years) (03/21/18)   Comparative Impact of Antiretrovirals on Human Platelet Activation (03/21/18)   LEUKOCYTES ARE KEY TO THE PRO-THROMBOTIC EFFECTS OF ABACAVIR (03/21/18)   Antiretroviral Drugs Associated with Subclinical Coronary Artery Disease. (03/21/18)   HIV-1 VIRAL REBOUND AND SAFETY OUTCOMES OF POSTPARTUM TREATMENT INTERRUPTION IN WOMEN (03/21/18)   SHORT-TERM ART INTERRUPTION HAS LITTLE EFFECT ON LEVELS OF INTEGRATED PROVIRAL DNA (03/20/18)   A5340: BRIEF ATI DOES NOT ALTER THE SIZE OR COMPOSITION OF THE LATENT HIV-1 RESERVOIR (03/20/18)   Impact of Treatment Interruption on HIV Reservoirs and Immunologic Parameters (03/20/18)   QUANTIFICATION OF REPLICATION COMPETENT LATENT HIV-1 IN GALT AND SEMEN Replication Competent HIV-1 in Reservoir-GALT/Rectal/Semen/Blood - Mark Mascolini (03/20/18)   DETERMINANTS OF HIV-1 RESERVOIR SIZE AND LONG-TERM DYNAMICS UNDER SUPPRESSIVE ART - Mark Mascolini (03/20/18)   No Evidence for Ongoing HIV-1 Replication in Lymph Nodes During Suppressive ART - Mark Mascolini (03/20/18)   P38 MAPK in vivo inhibition impacts SIV-mediated immune activation & CD4 T-cell loss (03/16/18)   Prevalence of Active Hepatitis B Among New York City MSM Initiating PrEP and PEP, 2016-2017 (03/16/18)   IMPACT OF METHOTREXATE ON ARTERIAL INFLAMMATION IN PERSONS WITH TREATED HIV (03/16/18)   LONGITUDINAL COGNITIVE OUTCOMES AFTER TREATMENT IN ACUTE HIV INFECTION (03/16/18)   Results of ACTG A5288: A Strategy Study in RLS [resource limited setting] for 3rd Line ART Candidates (03/16/18)   METHAMPHETAMINE USE INDEPENDENTLY PREDICTS PREMATURE AGING IN HIV+ INDIVIDUALS (03/16/18)   Low Prevalence of Hepatitis C Virus Among New York City MSM Initiating PrEP and PEP, 2016-2017 at NYC Sexual Health Clinics (03/15/18)   A treatment as prevention trial to eliminate HCV in HIV positive men who have sex with men: The Swiss HCVree Trial - e-health assisted behavioral intervention to reduce risk in HCV re-infection in MSM - Mark Mascolini (03/15/18)   FUELING THE EPIDEMIC: Low Spontaneous HCV Clearance in Big European HCV/HIV Cohort - Mark Mascolini (03/15/18)   MITOCHONDRIAL DYSFUNCTION IN WELL-SUPPRESSED PERINATALLY HIV-INFECTED CHILDREN ON ANTIRETROVIRAL THERAPY (03/14/18)   ViiV Healthcare Announces Positive Action Southern Initiative Expansion and Request for Proposals (03/14/18)   Lopinavir/ritonavir Induces Mitochondrial Toxicity in HIV-exposed Uninfected Children (03/14/18)   Metabolic Shut Down of CD4 T Cells Activity Induced by HAART (03/14/18)   Statin exposure is associated with decreased risk of cancer - Mark Mascolini (03/14/18)   Change in Soluble Glycoprotein VI When Switching From ABC/3TC to TAF/FTC (03/14/18)   PLATELET FUNCTION UPON SWITCHING TO TAF VS CONTINUING ABC: A RANDOMIZED SUBSTUDY - Mark Mascolini (03/14/18)   Protection against repeated vaginal SHIV challenges by bNAb 3BNC117 and 10-1074 - Mark Mascolini (03/14/18)   INCREASED RISK OF PERIPHERAL ARTERY DISEASE IN PERSONS WITH HIV COMPARED TO CONTROLS (03/13/18)   Bictegravir at CROI (03/13/18)   HIV Incidence and Adherence in DREAM -An Open-Label Trial of Dapivirine Vaginal Ring (03/12/18)   8 weeks of grazoprevir plus elbasvir for acute hepatitis C virus genotype 1 or 4 infection - the DAHHS 2 study - a single-arm, prospective, open-label, multicenter phase 3b trial (03/12/18)   BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/r AS FIRST LINE ART (03/12/18)   Amyloid uptake by PET imaging in older HIV+ individuals with cognitive impairment (03/12/18)   Asymptomatic Neurocognitive Impairment With HIV Marked by Brain Atrophy - Mark Mascolini (03/12/18)   Reversing Accelerated Aging in HIV patients: Metabolic and Mitochondrial Mechanisms (03/12/18)   LOWER MITOCHONDRIAL DNA COPY NUMBER IS ASSOCIATED WITH HIV & PREDICTIVE OF MORTALITY (03/12/18)   Cabotegravir long-acting protects macaques against repeated penile SHIV exposures (03/12/18)   IMPACT OF ART REGIMENS ON CSF VIRAL ESCAPE IN HIV-1 INFECTED ADULTS - Mark Mascolini (03/12/18)   Methotrexate Reins in CD8 Cells But Does Not Improve Endothelial Function - Mark Mascolini (03/12/18)   CROI - Non-AIDS Complications / Inflammation Markers-Kidney Disease-Plaque Predict Outcomes (03/12/18)   High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies (03/10/18)   NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV (03/09/18)   Virologic Response To 2-Drug ART Regimens Among Treatment-Experienced HIV+ Patients (03/09/18)   DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO-Recommended NRTI Backbone (03/09/18)   BRAIN 18F-FDG PET OF SIV-INFECTED MACAQUES AFTER TREATMENT INTERRUPTION OR INITIATION - (03/09/18)   Oral TAF/FTC PrEP Prevents Vaginal SHIV Infection in Monkeys - Mark Mascolini (03/09/18)   IBALIZUMAB FDA Product Insert (03/09/18)   POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART ACTG HIV Reservoirs Cohort study A5321 (03/09/18)   HIV-1 persists in CSF cells in half of individuals on long-term ART - Mark Mascolini (03/09/18)   New Positive Data on Trogarzo™ (ibalizumab-uiyk) Injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections (03/09/18)   SIV REBOUND IN THE SPINAL CORD AFTER STOPPING ART: A NOVEL CNS RESERVOIR (03/09/18)   Pharmacokinetics of Total and Unbound Darunavir in HIV-1-infected Pregnant Women Receiving a Darunavir/Cobicistat-based Regimen (03/09/18)   Pharmacokinetics of Total and Unbound Darunavir in HIV-1-infected Pregnant Women Receiving a Darunavir/Cobicistat-based Regimen (03/09/18)   HIV Treatment-experienced Patients Switched to D/C/F/TAF: Age, Gender, and Race Analyses (03/09/18)   Analysis of HIV Patients Switching to D/C/F/TAF by Prior ARV Treatment Experience (03/09/18)   Retreatment of Hepatitis C Infection in Patients Who Failed Glecaprevir/Pibrentasvir (03/09/18)   Age, Gender, and Race Analyses of D/C/F/TAF in HIV-1 Treatment-naïve Patients (03/08/18)   IBALIZUMAB SUSCEPTIBILITY & Potency vs ART Resistance - New HIV Drug for Multi-Drug Resistant Patients (03/08/18)   Antiviral Activity of Tenofovir Alafenamide Against HIV-1 with Thymidine Analog Mutation(s) and M184V (03/08/18)   Efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in virologically-suppressed, treatment-experienced and treatment-naïve women with human immunodeficiency virus type 1 (03/08/18)   High uptake and reduced HIV-1 incidence in an open-label trial of the dapivirine ring (03/08/18)   The Rapid ART Program Initiative for HIV Diagnoses (RAPID) in San Francisco (03/08/18)   IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS (03/08/18)   EFV and ATV/r "Profoundly Alter" Levels of Vaginal Ring Hormonal Contraceptives - Mark Mascolini (03/07/18)   IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS - (03/07/18)   San Francisco RAPID ART Program Halves Span From HIV Diagnosis to Suppression - Mark Mascolini (03/07/18)   Starting ART on Day of Home HIV Test Improves Linkage, Viral Suppression - Mark Mascolini (03/07/18)   Hyperkyphosis and Aging in the Women's Interagency HIV Study - Mark Mascolini (03/07/18)   Impact of Low Dose Methotrexate on Immune Activation and Endothelial Function in Treated HIV - Mark Mascolini (03/07/18)   Statin Use Linked to Lower Cancer Risk With or Without HIV - Mark Mascolini (03/07/18)   No Evidence of Residual Virus Replication in a Randomised Controlled Trial of Dolutegravir Intensification - (03/07/18)   PGT121 Combined with GS-9620 Delays Viral Rebound in SHIV-Infected Rhesus Monkeys - (03/07/18)   Persistent Detection of HIV RNA+ Cells With ART Started in Fiebig 1 & 2 vs Fiebig 3-5 - (03/07/18)   Safety and Efficacy of E/C/F/TAF in HIV-Infected Adults on Chronic Hemodialysis - (03/07/18)   Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 - (03/07/18)   FDA approves new HIV treatment (Long-Acting Ibalizumab) for patients who have limited treatment options - (03/07/18)   SERIOUS CLINICAL EVENTS IN HIV-POSITIVE PERSONS WITH CHRONIC KIDNEY DISEASE (CKD) - D:A:D - (03/07/18)   IL-6, D-dimer or T-cells: which best predict events or explain benefits of early ART? - (03/07/18)   Progression of Coronary Plaque: The MACS Longitudinal Coronary CT Angiography Study" - Mark Mascolini (03/07/18)   Carotid Plaque Predicts All-Cause Mortality in Women and Men With HIV: "Association of carotid artery atherosclerosis with mortality in HIV+ women and men" - Mark Mascolini (03/07/18)   INSTI-based initial ART in the HIV Outpatient Study [Integrase s Non-Integrase Viral Suppression/Duration of ART] - (03/07/18)   Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF: Week 96 Results - (03/07/18)   Distribution of Active PrEP Prescriptions and the PrEP-to-Need Ratio, US Q2 2017 - (03/07/18)   Low-Dose Oral MK-8591 Protects Monkeys From Rectal SHIV Infection - Mark Mascolini (03/07/18)   Low-Dose Hydrocortisone Improves Learning and Memory in Women With HIV - Mark Mascolini (03/06/18)   High-Intensity Exercise Has Edge Over Moderate Intensity in Older Group With HIV - Mark Mascolini (03/06/18)   Integrase Inhibitor Penetration Generally Worse in Lymphoid Tissue Than Blood Cells - Mark Mascolini (03/06/18)   Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial ACTG5257 - Mark Mascolini (03/06/18)   Multiple Low Doses of Nucleoside MK-8591 Strong in Healthy Volunteers - Long-Acting MK-8591 /Treatment / PrEP-vaginal/rectal tissue - Mark Mascolini (03/06/18)   Mortality Plateaued in 2001 in Large Baltimore Drug Injector Cohort / Mortality Steeply Increased due to Comorbidities - (03/06/18)   Pharmacokinetics of Bictegravir Administered Twice Daily In Combination With Rifampin - (03/06/18)   Similar Efficacy and Safety By Subgroup in DRIVE-AHEAD: DOR/3TC/TDF vs EFV/FTC/TDF - (03/06/18)   Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results - (03/06/18)   Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Women - (03/06/18)   POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART ACTG HIV Reservoirs Cohort study A5321 - (03/06/18)   Tenofovir Diphosphate in Dried Blood Spots is a Strong Predictor of Viral Suppression - (03/06/18)   Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen - (03/06/18)   DolPHIN-1: Dolutegravir vs Efavirenz when Initiating Treatment in Late Pregnancy - (03/06/18)   Impact of Raltegravir Intensification of first-line ART on IRIS in the REALITY trial (Reduction of EArly mortaLITY in HIV-infected adults and children starting ART) - (03/05/18)   MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV - (03/05/18)   Hair antiretroviral (ARV) levels strongly predict virologic outcomes in ACTG A5257 - (03/05/18)   Switch to Bictegravir/F/TAF Noninferior to Staying with DTG/ABC/3TC - written by Mark Mascolini (03/05/18)   Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial - written by Mark Mascolini (03/05/18)   INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24 - (03/05/18)   Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy®(Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine - (03/05/18)   Switch to Bictegravir/F/TAF From DTG and ABC/3TC - (03/05/18)   LOW DOSE MK-8591 PROTECTS RHESUS MACAQUES AGAINST RECTAL SHIV INFECTION - (03/05/18)   NIH bNAB+PGT121 Keeps Viral Suppression in 45% of Monkeys After ART Stop - (03/05/18)   Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys - (03/05/18)   Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - (03/05/18)